Longeveron (NASDAQ:LGVN) Upgraded at Roth Capital

Roth Capital upgraded shares of Longeveron (NASDAQ:LGVN) to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

A number of other research firms also recently weighed in on LGVN. Roth Mkm started coverage on Longeveron in a research note on Friday. They set a “buy” rating and a $10.00 price target for the company. Maxim Group cut their price objective on Longeveron from $15.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Longeveron in a research note on Monday, November 25th.

Longeveron Price Performance

LGVN opened at $2.08 on Thursday. Longeveron has a fifty-two week low of $0.77 and a fifty-two week high of $23.90. The business has a 50-day moving average of $2.02 and a 200-day moving average of $2.17. The company has a market capitalization of $30.87 million, a PE ratio of -0.33 and a beta of 0.31.

Longeveron (NASDAQ:LGVN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.19. Longeveron had a negative return on equity of 142.43% and a negative net margin of 967.49%. The company had revenue of $0.77 million during the quarter, compared to the consensus estimate of $0.34 million. During the same period last year, the business earned ($2.80) EPS. On average, equities research analysts expect that Longeveron will post -3.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new stake in Longeveron in the 2nd quarter valued at approximately $236,000. Geode Capital Management LLC grew its holdings in Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares during the last quarter. Finally, State Street Corp acquired a new stake in Longeveron in the 3rd quarter valued at approximately $29,000. 10.01% of the stock is owned by institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.